RT Journal Article
SR Electronic
T1 Real-world data on the use of teduglutide in a UK cohort: 4-year experience of a single centre
JF Frontline Gastroenterology
JO Frontline Gastroenterol
FD BMJ Publishing Group Ltd
SP 214
OP 226
DO 10.1136/flgastro-2024-102689
VO 16
IS 3
A1 Stevens, Phil
A1 Turner, Rebecca
A1 Doherty, Graeme
A1 Jordan, Dawn
A1 Leitch, Fiona
A1 Murray, Linda
A1 Wadsworth, John
YR 2025
UL http://fg.bmj.com/content/16/3/214.abstract
AB Background Phase IV outcome data of novel therapies in an orphan-disease need to be shared. Glucagon-like peptide-2 (GLP-2) analogues for short bowel syndrome chronic intestinal failure (SBS-cIF) were approved for use in NHS Scotland in 2020. The aim of this study was to report early experience introducing GLP-2 to a specialist intestinal failure service.Method Retrospective analysis of a patient database was used to describe changes in home parenteral support (HPS), patient tolerance and micronutrient balance following introduction of GLP-2 analogue. These were compared with changes in HPS patients weaned by adaptation, surgery or transplantation.Results Of 218 patients managed with HPS at the Glasgow Royal Infirmary between February 2020 and August 2024, 162 (74%) had SBS-cIF. 70 (43%) met inclusion criteria for teduglutide. 11 (15%) received teduglutide, with median dose of 3.0 mg/day during the study period. Overall, 8 (73%) achieved reduction of one or more nights HPS/week and 7 (64%) either an HPS reduction >1.5 L/day or >20% reduction in equivalent daily volumes at 6 months. 6 (55%) retained teduglutide use long term. Patients weaned from HPS with teduglutide compared with those weaned by other means had significantly better liver enzymes, vitamin C and manganese. Indices of renal function may reflect change in lean body mass. Significantly more teduglutide weaned patients had end jejunostomies.Conclusion GLP-2 analogue use reduced parenteral support requirement when integrated into our intestinal failure service. These treatments may have extra-enteric hepatoprotective consequences.Data are available upon reasonable request.